Arovella Therapeutics: Half Year Report and Appendix 4D
Filed with ASX · · 24 pages · English
Arovella Therapeutics Limited Appendix 4D Half-year report 1. Company details 2. Results for announcement to the market Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss from continuing operations for the company after providing for income tax amounted to $1,878,707 (31 December 2024: $1,461,582). 4. Control gained over entities
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Positive FDA Type D Meeting Outcome
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
Later from Arovella Therapeutics
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
- Board Refresh and CEO Resignation
- Arovella Appoints Acting CEO
- Clinical manufacturing batch released, first site activated
- The path to first patient dosing
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics